Company: DARE
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001401914-25-000044
Chunk: 43

Company: Dare Bioscience, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 43
---
. The warrants include certain rights in favor of the holders upon a “fundamental transaction” as described in the warrants, including the right of the holders to receive from the Company or the successor entity an amount of cash equal to the Black-Scholes value (as described in the warrants) of the unexercised portion of the warrants on the date of the consummation of such fundamental transaction. As of June 30, 2025, none of the warrants have been exercised.Summary of Warrant ActivityA summary of warrant activity during the six months ended June 30, 2025 is presented below:Common StockNumber of Shares Underlying WarrantsWeighted Average Exercise PriceWeighted Average Remaining Life in YearsIntrinsic ValueOutstanding December 31, 2024, 1,268,572 $7.49 4.10$— Granted— — Exercised— — Forfeited or expired— — Outstanding and exercisable June 30, 2025, 1,268,572 $7.49 3.60$— 

16

5.    STOCK-BASED COMPENSATION

2014 Employee Stock Purchase PlanThe Company’s 2014 Employee Stock Purchase Plan, or the ESPP, became effective in April 2014, but no offering period has been initiated thereunder since January 2017. In June 2024, the Company's board of directors suspended the ESPP. There was no stock-based compensation related to the ESPP for the six months ended June 30, 2025 or June 30, 2024.Amended and Restated 2014 Stock Incentive PlanThe Amended and Restated 2014 Stock Incentive Plan, or the Amended 2014 Plan, provided for the grant of stock-based awards to employees, directors, consultants and advisors. As a result of the approval of the 2022 Plan (as defined below) by the Company's stockholders in June 2022, no further awards have been or will be granted under the Amended 2014 Plan since such approval. Outstanding awards previously granted under the Amended 2014 Plan continue to remain outstanding in accordance with their terms.2022 Stock Incentive PlanIn April 2022, the Company's board of directors approved the Daré Bioscience, Inc. 2022 Stock Incentive Plan, or the 2022 Plan, which was subsequently